Otsuka - About the company
Otsuka is a public company based in Minato (Japan), founded in 1921 by Busaburo Otsuka. It operates as a Manufacturer of generic pharmaceuticals and nutraceuticals. Otsuka has raised an undisclosed amount in funding. The company has 1239 active competitors, including 43 funded and 337 that have exited. Its top competitors include companies like Bayer, Teva Pharmaceuticals and Wockhardt.
Company Details
Otsuka is a Japanese generic pharma company that manufactures and markets pharmaceuticals and nutraceuticals. In pharmaceuticals, the therapeutic areas it focuses on are CNS, cardiovascular, oncology, and ophthalmology. In Jan.2015, Otsuka acquired a US-based company, Avanir Pharmaceuticals. In nutraceuticals, the company sells electrolyte rehydration drinks, balanced nutrition foods, soy-based foods etc. In 2022, the company recorded annual revenues of $13.21B and a net profit of $1.02B.
- Website
- otsuka.com/jp/
- Registered Address
- 東京都,千代田区,神田司町2丁目9番地
Key Metrics
Founded Year
1921
Location
Minato, Japan
Stage
Public
Latest Funding Round
Investors
Ranked
15th among 1239 active competitors
Annual Revenue
$1B+ as on Jun 30, 2026
Employee Count
50 - 199 as on Mar 01, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Otsuka
Otsuka is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Otsuka Holdings Co., Ltd. CIN: 4010001118786 , Japan, Active | Oct 05, 2015 | $1B+ (As on Jun 30, 2026) | - | - |
Otsuka's IPO details
Otsuka got listed on Dec 15, 2010.
Click here to take a look at Otsuka's IPO in detail
Sign up to download Otsuka's company profile
Otsuka's funding and investors
Otsuka has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Aug 10, 2021 for $*****. 1 investor participated in its latest round. Otsuka has 2 institutional investors.
Here is the list of recent funding rounds of Otsuka:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 10, 2021 | 4711224 | Grant (prize money) | 2988211 | 5426789 | 6661451 | 6112562 |
View details of Otsuka's funding rounds and investors
Otsuka's founders and board of directors
Founder? Claim ProfileThe founders of Otsuka is Busaburo Otsuka. Tatsuo Higuchi is the CEO of Otsuka.
Here are the details of Otsuka's key team members:
- Busaburo Otsuka: Former Founder of Otsuka and founder of 1 other company.
View details of Otsuka's Founder profiles and Board Members
Otsuka's employee count trend
Otsuka has 50 - 199 employees as of Mar 26. Here is Otsuka's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Otsuka's Competitors and alternates
Top competitors of Otsuka include Bayer, Teva Pharmaceuticals and Wockhardt. Here is the list of Top 10 competitors of Otsuka, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Manufacturer of drugs | - | 76/100 | ||
2nd | Teva Pharmaceuticals 1901, Petah Tikva (Israel), Public | Traditional company engaged in manufacturing generics | $500M | 75/100 | |
3rd | Manufacturer of pharmaceuticals, biotechnology products, and active pharmaceutical ingredients | - | 71/100 | ||
4th | Biological E 1953, Hyderabad (India), Funding Raised | Developer of vaccines for treating multiple diseases | - | 69/100 | |
5th | Manufacturer of APIs, generic drugs, and formulation development services | - | 69/100 | ||
6th | The Alvogen 2009, Morristown (United States), Acquired | Developer and marketer of pharmaceutical products | $156M | 69/100 | |
7th | Developer, manufacturer, and markets a broad range of pharmaceutical products | $50M | 68/100 | ||
8th | Amneal 2002, Bridgewater (United States), Public | Manufacturer of generics formulations | - | 68/100 | |
9th | Laboratorio Reig Jofre 2000, Barcelona (Spain), Public | Manufacturer of pharmaceutical products and food supplements | - | 68/100 | |
10th | Strides Pharma Science 1990, Bengaluru (India), Public | Manufacturer of generic pharmaceutical products and various specialty medical formulations | - | 68/100 | |
15th | Manufacturer of generic pharmaceuticals and nutraceuticals | - | 66/100 |
Looking for more details on Otsuka's competitors? Click here to see the top ones
Otsuka's Investments and acquisitions
Otsuka has made 10 investments in companies including REMARE and VIE STYLE. Otsuka has also acquired 11 companies including Visterra and ReCor Medical.Here is the list of investments & acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jul 31, 2024 | Investments | 2023 | Matsusaka (Japan) | |
Mar 07, 2024 | Investments | 2013 | Kamakura (Japan) | |
Mar 30, 2023 | Investments | 2017 | Melbourne (Australia) |
See all investments and acquisitions by Otsuka
Reports related to Otsuka
Here is the latest report on Otsuka's geography:
News related to Otsuka
Media has covered Otsuka for a total of 32 events in the last 1 year, 14 of them have been about company updates and 1 about partnerships.
•
•
Otsuka and Ionis Report Positive Phase III Trial Data for FUS-ALS Therapy Ulefnersenhttps://www.clinicaltrialsarena.com/•Sep 23, 2026•Ionis, Otsuka
•
Otsuka Pharmaceutical reports expanded Phase IIIb results for Simtriyo in adult ADHDhttps://www.clinicaltrialsarena.com/•Sep 21, 2026•Otsuka
•
•
Otsuka’s Zipalertinib Combo Hits Phase 3 Goal in Targeted Lung Cancer TrialTipRanks•Aug 12, 2026•Otsuka
•
Otsuka Pharmaceutical Announces Positive Phase 3 VISIONARY Trial Results for IgA Nephropathy TreatmentWorld Business Outlook•Aug 04, 2026•Otsuka
•
Otsuka's ADHD Drug Simtriyo Receives FDA Approval, Opening New Treatment ClassBioSpace•Jul 27, 2026•Otsuka
•
Otsuka ICU Medical outlays $500m to expand US manufacturing footprintMedicalDeviceNetwork•Jul 10, 2026•Otsuka
•
Otsuka's centanafadine shows promise in ADHD, easing symptoms and anxiety ahead of FDA decisionBioSpace•Jun 26, 2026•Otsuka
•
Otsuka touts new IgAN evidence as it seeks full approval for VoyxactEndpoints•Jun 04, 2026•Otsuka, Transcend Therapeutics, Otsuka America Pharmaceutical
Are you a Founder ?
FAQs about Otsuka
Explore our recently published companies
- Linzess - Boston based, Unfunded company
- CTCBIO - Seoul based, 1993 founded, Public company
- Apollo Generics - United Kingdom based, 2006 founded, Unfunded company
- Hubei Tangren Pharmaceutica - Wuhan based, 2003 founded, Unfunded company
- Rontis - Zug based, 1986 founded, Unfunded company
- Sydna Farma - Jakarta based, 2007 founded, Unfunded company